Skip to content

The effect of Virtual Reality Exposure Therapy (VRET) on social participation in people with a psychotic disorder: a multi-site randomized controlled trial.

The effect of Virtual Reality Exposure Therapy (VRET) on social participation in people with a psychotic disorder: a multi-site randomized controlled trial. - Virtual Reality Exposure Therapy in Psychosis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON40358
Enrollment
160
Registered
2014-04-23
Start date
2014-04-07
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychosis Psychotic disorders - and also Social Anxiety

Interventions

VRET treatment has a maximum of sixteen treatment sessions with a maximum of 60 minutes each. Existing CBT protocols will be adapted for VRET treatment in one area only: exposure in vivo will be rep
providing treatment rationale, behavioral experiments, reducing safety behavior and attention training. Starting with exposure exercises for social situations lowest in patients anxiety hierarchy, f

Sponsors

Vrije Universiteit
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients first diagnosed with a non-affective psychotic disorder experiencing at least mild paranoia and/or social anxiety.

Exclusion criteria

Exclusion criteria: IQ under 70 Insufficient command of the Dutch language Epilepsy

Design outcomes

Primary

MeasureTime frame
The main outcome will be social participation. Objective social participation is measured as the time spend in the company of other people and the type of people spend time with. Subjective social participation is measured as momentary paranoia, perceived social threat and event stress as experienced in situations with other people. Social participation will be measured by the PsyMate Experience Sampling Method before and at end of treatment, and at 3 months follow-up.

Secondary

MeasureTime frame
Quality of life, stigmatization, safety behavior, side-effects VRET, acceptability of VRET for patients and therapists, emotional and social wellbeing. Medication adherence during participation in the study using the Brief Adherence Rating scale to control for medication effects.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)